Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real-world analysis

Zhang, Wencong1; Xing, Mingyou1; Sun, Wenjin2; Chen, Jia1; Xie, Nana1; Cai, Yuan3; Wang, Ying3; Li, Niuniu3; Jiang, Yujin3; Zhang, Fan3; Wang, Yanfeng3; Zeng, Qingjin3; Ji, Yanhua3; Xu, Cheng3; Jiang, Chunmei4; Song, Jianxin1,6; Li, Guojun3,5

2023-05-01

10.1111/jvh.13792

JOURNAL OF VIRAL HEPATITIS   影响因子和分区

1352-0504

1365-2893

Although there are therapeutic advantages for hepatitis B virus (HBV) withpegylated interferon alpha (peg-IFN alpha) treatment compared with nucleos(t)ide analog (NAs) therapy, the effect difference in infected population at different phases has not been well established. We studied the clinical efficacy of peg-IFN alpha in two populations with HBV infection, including inactive HBsAg carrier (IHC) and chronic hepatitis B (CHB). A total of 328 HBV-infected patients were included in this real-world analysis. Patients were divided into two groups according to the infected stages. Peg-IFN alpha monotherapy or combination therapy with NAs were used in IHCs, and peg-IFN alpha added-on NAs therapy was applied to patients with CHB. The primary efficacy endpoint was HBsAg loss at Week 24. Results: The Kaplan-Meier cumulative rates of HBsAg loss were 39.50% (n = 47/119) in IHC group and 28.71% (n = 60/209) in CHB group at Week 24 (p < .05). After Propensity Score Matching (PSM), the HBsAg loss rates were 36.84% (n = 35/95) and 32.63% (n = 31/95), respectively (p > .05). Patients with baseline HBsAg level < 100 IU/ml achieved higher rates of HBsAg clearance in IHC and CHB group (before PSM: 47.44% vs. 42.86%, after PSM: 49.12% vs. 45.83%, all p values > .05). Baseline HBsAg level and its level decline from baseline to Week 12 can be as the predictors for HBsAg loss at Week 24 in both groups. Hence, the efficacy of HBsAg clearance was broadly similar between IHCs and NA-treated CHB patients during the early peg-IFN alpha therapy. A significant downward trend of HBsAg level was observed in both groups during peg-IFN alpha therapy.

chronic hepatitis B HBsAg loss inactive HBsAg carrier nucleos(t)ide analogs pegylated interferon

SCI

英语

通讯

null[JCYJ20190812151601664] ; null[2016KYA162] ; null[2020076]

Gastroenterology & Hepatology ; Infectious Diseases ; Virology

Gastroenterology & Hepatology ; Infectious Diseases ; Virology

WOS:000907909700001

WILEY

IMMUNOLOGY

Web of Science

1.Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Infect Dis, Wuhan, Peoples R China
2.Ezhou Cent Hosp, Dept Infect Dis, Ezhou, Peoples R China
3.Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Affiliated Hosp 2, Natl Clin Res Ctr Infect Dis,Dept Liver Dis,State, Shenzhen, Peoples R China
4.Peoples Hosp Longhua, Dept Infect Dis, Shenzhen, Peoples R China
5.Shenzhen Third Peoples Hosp, Dept Liver Dis, 29 Bulan Rd, Shenzhen 518112, Peoples R China
6.Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Infect Dis, 1095 Jiefang Ave, Wuhan 430030, Peoples R China

Zhang, Wencong,Xing, Mingyou,Sun, Wenjin,et al. Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real-world analysis[J]. JOURNAL OF VIRAL HEPATITIS,2023,30(5).

Zhang, Wencong.,Xing, Mingyou.,Sun, Wenjin.,Chen, Jia.,Xie, Nana.,...&Li, Guojun.(2023).Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real-world analysis.JOURNAL OF VIRAL HEPATITIS,30(5).

Zhang, Wencong,et al."Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real-world analysis".JOURNAL OF VIRAL HEPATITIS 30.5(2023).